Welcome to our dedicated page for Femasys news (Ticker: FEMY), a resource for investors and traders seeking the latest updates and insights on Femasys stock.
Femasys Inc. develops biomedical products for women’s reproductive health, with news centered on fertility treatment, fallopian tube assessment, and non-surgical permanent birth control. Its portfolio includes FemaSeed intratubal insemination, FemaSeed Complete for in-office fertility care, FemVue for ultrasound-based fallopian tube evaluation, FemBloc permanent birth control, and related diagnostic products such as FemChec.
Recurring updates cover product commercialization in OB/GYN settings, international distribution and market access, regulatory approvals outside the United States, U.S. clinical and regulatory development for FemBloc, reimbursement-related developments, financing, operating results, and governance changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Femasys Inc. (NASDAQ: FEMY) announced a definitive agreement for a registered direct offering of 3,196,722 shares at $1.22 each, alongside a concurrent private placement of unregistered warrants for the same number of shares, exercisable at $1.095. The gross proceeds are expected to be approximately $3.9 million, aimed at working capital and general corporate purposes. The offering is set to close around April 20, 2023, pending customary conditions. H.C. Wainwright & Co. is serving as the exclusive placement agent. Both the registered and unregistered offerings have specific regulatory frameworks and cannot be publicly reoffered without appropriate registration.
Femasys Inc. (NASDAQ: FEMY) has received product approval from Health Canada for its innovative infertility solution, FemaSeed®. This first-of-its-kind artificial insemination approach aims to deliver sperm directly to the fallopian tubes, making it a less invasive and more affordable alternative to traditional methods like IVF. FemaSeed complements Femasys' existing product, FemVue®, which assesses fallopian tube patency. The company is also progressing towards a U.S. commercial launch in 2024, pending FDA clearance. CEO Kathy Lee-Sepsick emphasized that these advancements will provide safe and cutting-edge options for couples facing infertility.
Femasys Inc. (NASDAQ: FEMY) reported its 2022 financial results, revealing a net loss of $11.39 million, equating to $0.96 per share. Despite a 2.2% increase in sales to $1.21 million, research and development expenses rose significantly to $5.81 million, driven by clinical trial support and personnel costs. The gross margin decreased to 63.4% from 68.6% in 2021. Femasys continues to advance its clinical programs for FemBloc® and FemaSeed®, with notable enrollment progress in pivotal trials. The company has sufficient cash, expected to fund operations into Q1 2024, while recently launching commercial products FemCath™ and FemCerv®.
Femasys Inc. (NASDAQ: FEMY) announced its CEO, Kathy Lee-Sepsick, will speak at the South By Southwest (SXSW) 2023 Conference in Austin, Texas, from March 10-19, 2023. She is set to participate in a panel titled “The Post-Roe Fertility Journey” on March 11, 2023, discussing women's health considerations post-Roe regarding fertility management. Femasys focuses on developing minimally invasive technologies for reproductive health, including FemBloc® for permanent birth control and FemaSeed® for infertility. Their marketed products include FemVue® for fallopian tube assessment and FemCerv® for tissue sampling.